3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
2
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Conditions
Small Cell Lung Carcinoma
62
Leukemia, Myeloid, Acute
14
Carcinoma, Non-Small-Cell Lung
14
Lung Neoplasms
10
Lymphoma, Non-Hodgkin
9
Lymphoma, Large B-Cell, Diffuse
9
Recurrence
8
Neoplasms
8
Parkinson Disease 4, Autosomal Dominant Lewy Body
6
Lymphoma
5
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Ovarian Neoplasms
3
Leukemia
3
Hodgkin Disease
3
Extensive Stage Small Cell Lung Cancer
3
Carcinoma, Small Cell
3
Small Cell Lung Cancer Extensive Stage
2
SCLC
2
Osteosarcoma
2
Neoplasm Metastasis
2
Lymphoma, B-Cell
2
Lymphatic Diseases
2
Immunoproliferative Disorders
2
Hematologic Diseases
2
Glioblastoma
2
Ependymoma
2
Advanced Solid Tumors
2
Widespread Small Cell Lung Cancer
1
Unresectable Locally Advanced or Metastatic Solid Tumors
1
Squamous Cell Carcinoma of Head and Neck
1
Interventions
pembrolizumab
126
Cisplatin
47
Cetuximab
46
Nivolumab
36
Carboplatin
33
Paclitaxel
28
Fluorouracil
26
Docetaxel
17
avelumab
11
Radiotherapy
11
Cyclophosphamide
11
cemiplimab
10
atezolizumab
10
durvalumab
9
Ipilimumab
8
spartalizumab
7
budigalimab
7
Gemcitabine
7
Capecitabine
7
tremelimumab
6
lenvatinib
6
fludarabine
6
Pemetrexed
6
epacadostat
5
Fulvestrant
5
130-nm albumin-bound paclitaxel
5
zimberelimab
4
tislelizumab
4
Trastuzumab
4
Oxaliplatin
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Squamous Cell Carcinoma of Head and Neck
×
Etoposide
×
Clear all
NCT03509012
2025-01-14
CLOVER
AstraZeneca
Phase 1
Completed
105 enrolled